The Evidence Pack: How a New Antibody Drug is Triggering Natural Tooth Regrowth in Human Trials

For decades, the ultimate solution to a missing tooth has been a titanium screw driven into the jawbone. While dental implants and dentures restore function, they remain artificial replacements that cannot perfectly mimic the biomechanics of living tissue. Now, a paradigm shift is quietly advancing in Japanese laboratories. Researchers are moving closer to a reality where the human body can be coaxed into regrowing its own missing teeth, replacing artificial prosthetics with natural enamel and dentin.[1][2]

The breakthrough centers on an experimental drug called TRG035, developed by Toregem BioPharma, a spin-out from Kyoto University. In June 2026, the company announced it had successfully completed its Phase I human clinical trials and secured $5.3 million in new funding to launch Phase II. The milestone marks the transition of tooth regeneration from a theoretical concept into a tangible clinical pipeline, capturing the attention of the global dental industry.

To understand how TRG035 works, it is necessary to look at the biological mechanisms that control dental development. Humans naturally grow two sets of teeth over their lifetime: deciduous "baby" teeth and permanent adult teeth. However, researchers have long hypothesized that humans retain vestigial tooth buds—dormant cellular starting points hidden within the jaw that possess the genetic blueprint to form a "third dentition."

The reason these third teeth never develop is due to a specific protein called USAG-1 (uterine sensitization-associated gene-1). USAG-1 acts as a biological brake, suppressing the growth of these dormant buds to regulate the number of teeth a healthy adult develops. TRG035 is a humanized monoclonal antibody designed specifically to target and neutralize this protein. By blocking USAG-1, the drug effectively removes the brake, allowing the dormant tooth bud to activate and grow into a fully formed natural tooth.[1]

The foundational science behind this approach was solidified in a landmark 2021 study published in Scientific Reports. Kyoto University researchers, led by Dr. Katsu Takahashi, demonstrated that inhibiting USAG-1 successfully stimulated new tooth growth in mice suffering from tooth agenesis. Subsequent animal trials expanded to ferrets and dogs, which possess dental patterns much closer to humans. In these models, the antibody triggered the regeneration of missing premolars that functioned normally and integrated seamlessly with surrounding jaw tissue.[1][2]

Moving from animal models to human applications is notoriously difficult, prompting the rigorous Phase I safety trial that began in late 2024 at Kyoto University Hospital. The initial study enrolled 30 healthy men between the ages of 30 and 64, all of whom were missing at least one molar. Participants received a single intravenous dose of TRG035 or a placebo in a dose-escalation design, primarily to test how the human body processes the antibody and to identify any adverse reactions.[1][2]

The results of the Phase I trial have been highly encouraging. Preliminary analyses released in early 2026 confirmed that the drug cleared the safety hurdle without triggering any serious adverse events or systemic toxicity. While this first stage was not designed to prove final efficacy—acting more as a safety check before expanding the patient pool—the clean safety profile allowed regulators to greenlight the next crucial phase of development.

With Phase II trials now funded and preparing to launch, Toregem BioPharma is shifting its focus to the patients who need this technology most urgently: children with severe congenital hypodontia. This rare genetic disorder is characterized by the absence of six or more permanent teeth from birth. For these pediatric patients, the clinical stakes are exceptionally high, affecting their ability to chew, speak, and develop normal jaw structures.

Traditional dental solutions are severely limited for young children with hypodontia. Because their jawbones are still growing, permanent titanium implants cannot be safely placed until late adolescence. As a result, children are often forced to rely on removable dentures for years, which can cause significant functional and psychological distress. TRG035 offers a potential biological cure that could grow natural teeth in tandem with the child's developing jaw.[1]

Recognizing the profound impact this treatment could have, Japan's health ministry granted TRG035 orphan drug status in 2025. This designation, reserved for treatments targeting rare diseases, provides Toregem with tax incentives, grant funding, and a prioritized regulatory review process. The upcoming Phase IIa study will specifically involve young children with congenital missing teeth, testing whether the antibody can reliably trigger tooth formation in a pediatric population.[1][2]

While the immediate focus remains on congenital conditions, the ultimate ambition for TRG035 is far broader. Researchers hope to eventually adapt the treatment for adults suffering from acquired tooth loss caused by severe decay, gum disease, or traumatic injury. According to the World Health Organization, complete tooth loss affects roughly 7% of adults globally, rising to 23% among those over the age of 60. A regenerative alternative to dentures and implants would represent one of the largest commercial markets in modern medicine.[2]

Despite the optimism, clinical experts caution that significant hurdles remain before tooth-regrowing drugs become a routine part of adult dentistry. One primary concern is localized delivery. Researchers must ensure that the systemic antibody only triggers tooth growth at the specific site of the missing tooth, rather than causing unwanted dental development across the entire jaw.

Furthermore, the newly grown teeth must prove capable of properly connecting to the jaw's complex network of nerves and blood vessels. They must also align naturally with the patient's existing dentition to ensure a correct bite and prevent structural issues. Proving this level of functional integration in human adults will require extensive, multi-year Phase III clinical trials.

Cost will also be a major factor in the treatment's accessibility. Early estimates suggest that the initial commercial price could hover around $11,000 per tooth. While this is significantly higher than the cost of a standard dental implant, proponents argue that the long-term benefits of a living, self-repairing natural tooth could justify the premium, particularly if economies of scale eventually drive the price down.

The timeline for public availability remains ambitious but grounded. Kitano Hospital and Toregem BioPharma are officially targeting a 2030 commercial release for the pediatric hypodontia treatment, pending successful outcomes in the upcoming trials. For adult acquired tooth loss, the horizon is likely further out, requiring separate regulatory approvals and broader efficacy data.[1]

For now, the successful completion of Phase I trials marks a historic milestone in regenerative medicine. The concept of growing a new tooth is no longer confined to science fiction or isolated laboratory experiments. As TRG035 advances into Phase II, the dental industry is preparing for a future where the drill and the implant may eventually share space with biological therapies that harness the body's own dormant potential.